Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Afrocentric Investment's 3-Year RORE % for the quarter that ended in Dec. 2025 was 94.56%.
The industry rank for Afrocentric Investment's 3-Year RORE % or its related term are showing as below:
JSE:ACT's 3-Year RORE % is ranked better than 90.76% of 606
companies
in the Healthcare Providers & Services industry
Industry Median: 0.56
vs JSE:ACT: 94.56
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Afrocentric Investment 3-Year RORE % Related Terms
Afrocentric Investment 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:ACT vs HCA, THC, DVA: 3-Year RORE % Comparison
For the Medical Care Facilities subindustry, Afrocentric Investment's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Afrocentric Investment 3-Year RORE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Afrocentric Investment's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Afrocentric Investment's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.
Afrocentric Investment (JSE:ACT) has a 3-Year RORE % of 94.56 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Afrocentric Investment and its competitors. According to the industry distribution chart, Afrocentric Investment ranks #56 out of 606 companies in the Healthcare Providers & Services industry, placing it in the top 9.2%.
Is Afrocentric Investment's 3-Year RORE % too high?
Afrocentric Investment's current 3-Year RORE % is 94.56. The Healthcare Providers & Services industry median 3-Year RORE % is 0.56. Afrocentric Investment's value of 94.56 is 16785.7% above this industry median. Based on the distribution chart, Afrocentric Investment ranks #56 out of 606 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Afrocentric Investment has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Afrocentric Investment's 3-Year RORE % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Afrocentric Investment ranks #56 out of 606 companies for 3-Year RORE %. This places Afrocentric Investment in the top 9% of its industry — outperforming the majority of peers. The industry median 3-Year RORE % is 0.56. Afrocentric Investment's value of 94.56 is 16785.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Healthcare Providers & Services company?
The median 3-Year RORE % among Healthcare Providers & Services companies is 0.56, based on 606 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Afrocentric Investment's current 3-Year RORE % of 94.56 is 16785.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Afrocentric Investment and its competitors. For the Healthcare Providers & Services industry, the median 3-Year RORE % is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Afrocentric Investment's current 3-Year RORE % is 94.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Afrocentric Investment stock overvalued right now?
Based on GuruFocus' analysis, Afrocentric Investment (JSE:ACT) is currently considered Possible Value Trap. The stock's GF Value™ is R2.09, compared to a current price of R0.85 — trading 59.3% below its estimated fair value. The current 3-Year RORE % is 94.56 and 16785.7% above the Healthcare Providers & Services industry median of 0.56. Afrocentric Investment's overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Afrocentric Investment (JSE:ACT), the current 3-Year RORE % is 94.56 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Afrocentric Investment (JSE:ACT) Overvalued in 2026?
Based on GuruFocus' analysis, Afrocentric Investment stock appears to be undervalued.
The current stock price of R0.85 is trading 59.3% below its estimated GF Value™ of R2.09.
GuruFocus considers Afrocentric Investment to be Possible Value Trap.
Key valuation signals for JSE:ACT:
3-Year RORE %: 94.56
GF Value™: R2.09 vs. price of R0.85 (59.3% below fair value)
Industry Position: 16785.7% above the Healthcare Providers & Services median (#56 of 606)
No single metric tells the full story. See the JSE:ACT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Afrocentric Investment Corp Ltd is an investment holding company providing specialised services and products to the public and private healthcare sectors. It focuses on making quality healthcare accessible and affordable to members and beneficiaries, with the principal objective of ensuring the delivery of efficient health management services and the distribution of quality products. Its business segments include Healthcare SA, comprising medical scheme administration and health risk management services; Healthcare Retail, comprising pharmaceutical sales and services; Healthcare Africa, comprising healthcare services outside South Africa in Namibia and Mauritius; and IT-related services predominantly within South Africa. It operates across South Africa, Botswana, Mauritius, and Namibia.
52GF Score
Get the complete analysis for JSE:ACT
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:ACT has been successfully added to your 
